Arvinas will discuss 2025 financial results and updates in a live webcast on February 24, 2026.
Quiver AI Summary
Arvinas, Inc., a biotechnology company focused on targeted protein degradation, will host a live webcast on February 24, 2026, at 8:00 a.m. ET to discuss its fourth quarter and full year 2025 financial results along with a corporate update. The event will be accessible on the investor page of the Arvinas website, where a replay will also be available afterward. The company is advancing various clinical programs using its PROTAC platform, with investigational drugs targeting diseases such as neurodegenerative disorders and cancers. Arvinas is based in New Haven, Connecticut, and continues its mission to develop therapies that improve patient outcomes.
Potential Positives
- Management will provide a corporate update and financial results review, indicating transparency and engagement with investors.
- The development of multiple investigational drugs demonstrates a robust pipeline and commitment to addressing significant medical needs.
- Focus on innovative protein degradation therapies positions Arvinas at the forefront of biotechnology advancements.
Potential Negatives
- There is no mention of any positive outcomes or progress regarding the clinical trials for the investigational drugs, which may raise concerns about their efficacy and the company's future prospects.
- Specific financial results for Q4 and full year 2025 have not been disclosed in advance of the webcast, potentially resulting in investor uncertainty or speculation prior to the event.
- As a clinical-stage company, Arvinas may face substantial risks related to the success of their drug candidates, and a lack of clear guidance in the release could amplify investor anxieties regarding their pipeline.
FAQ
When will Arvinas announce its fourth quarter and full year 2025 financial results?
Arvinas will announce the financial results on February 24, 2026, at 8:00 a.m. ET.
How can I access the Arvinas webcast?
The webcast can be accessed under “Events and Presentations” on the investor page of the Arvinas website.
Will there be a replay of the webcast available?
Yes, a replay of the webcast will be available on the Arvinas website after the event.
What is Arvinas known for?
Arvinas is known for developing a new class of drugs based on targeted protein degradation through its PROTAC platform.
Where is Arvinas headquartered?
Arvinas is headquartered in New Haven, Connecticut.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ARVN Insider Trading Activity
$ARVN insiders have traded $ARVN stock on the open market 2 times in the past 6 months. Of those trades, 1 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $ARVN stock by insiders over the last 6 months:
- BRIGGS MORRISON purchased 30,000 shares for an estimated $227,010
- DAVID K LOOMIS (Chief Accounting Officer) sold 230 shares for an estimated $2,274
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$ARVN Hedge Fund Activity
We have seen 99 institutional investors add shares of $ARVN stock to their portfolio, and 122 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CITADEL ADVISORS LLC removed 3,522,849 shares (-95.9%) from their portfolio in Q3 2025, for an estimated $30,014,673
- LOGOS GLOBAL MANAGEMENT LP added 2,275,000 shares (+68.9%) to their portfolio in Q3 2025, for an estimated $19,383,000
- TCG CROSSOVER MANAGEMENT, LLC added 1,617,365 shares (+inf%) to their portfolio in Q3 2025, for an estimated $13,779,949
- CAPTION MANAGEMENT, LLC removed 1,343,029 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $11,442,607
- VANGUARD GROUP INC removed 1,331,629 shares (-15.6%) from their portfolio in Q4 2025, for an estimated $15,793,119
- PRICE T ROWE ASSOCIATES INC /MD/ removed 1,246,656 shares (-93.5%) from their portfolio in Q3 2025, for an estimated $10,621,509
- D. E. SHAW & CO., INC. added 1,196,433 shares (+55.6%) to their portfolio in Q3 2025, for an estimated $10,193,609
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$ARVN Analyst Ratings
Wall Street analysts have issued reports on $ARVN in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Stephens & Co. issued a "Overweight" rating on 11/10/2025
- BTIG issued a "Buy" rating on 09/18/2025
To track analyst ratings and price targets for $ARVN, check out Quiver Quantitative's $ARVN forecast page.
$ARVN Price Targets
Multiple analysts have issued price targets for $ARVN recently. We have seen 6 analysts offer price targets for $ARVN in the last 6 months, with a median target of $15.0.
Here are some recent targets:
- Yigal Nochomovitz from Citigroup set a target price of $15.0 on 01/06/2026
- Etzer Darout from Barclays set a target price of $18.0 on 12/17/2025
- Sudan Loganathan from Stephens & Co. set a target price of $15.0 on 11/10/2025
- Derek Archila from Wells Fargo set a target price of $15.0 on 11/06/2025
- Jeet Mukherjee from BTIG set a target price of $14.0 on 10/30/2025
- Paul Choi from Goldman Sachs set a target price of $6.0 on 10/15/2025
Full Release
NEW HAVEN, Conn., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will review fourth quarter and full year 2025 financial results and provide a corporate update during a live webcast on Tuesday, February 24, 2026 at 8:00 a.m. ET.
The webcast can be accessed under “Events and Presentations” on the investor page of the Arvinas website. A replay of the webcast will be available on the Arvinas website at www.arvinas.com following the completion of the event.
About Arvinas
Arvinas (Nasdaq: ARVN) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through its PROTAC (PROteolysis TArgeting Chimera) protein degrader platform, Arvinas is pioneering the development of protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas is currently progressing multiple investigational drugs through clinical development programs, including ARV-102, targeting LRRK2 for neurodegenerative disorders; ARV-806, targeting KRAS G12D for mutated cancers, including pancreatic and colorectal cancers; ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; and vepdegestrant, targeting the estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer. Arvinas is headquartered in New Haven, Connecticut. For more information about Arvinas, visit www.arvinas.com and connect on LinkedIn and X .
Contacts
Investors:
Jeff Boyle
+1 (347) 247-5089
[email protected]
Media:
Kirsten Owens
+1 (203) 584-0307
[email protected]
